EVALUATION OF THE EFFICACY 5-FLUOROURACIL ON ERECTILE FUNCTION IN PATIENTS UNDER SURGICAL TREATMENT OF BENIGN PROSTATE HYPERPLASIA
Introduction. The prevalence of erectile dysfunction in benign prostatic hyperplasia (BPH) is 5.2-40%. Urethral strictures as a complication of transurethral resection of the prostate is a risk factor for the development of postoperative erectile dysfunction.
The purpose of the study is to evaluate the effectiveness of the prophylactic use of 5-fluorouracil in relation to erectile dysfunction in patients undergoing surgery for BPH.
Materials and methods. The study included 246 patients who underwent surgery, with an average age of 70.0±8.0 years. The main group included 124 patients who, in addition to the standard postoperative treatment in the hospital, received prophylactic intervention after surgery in the form of washing with a solution of 5-fluorouracil using a modified three-way catheter. The control group consisted of 122 combined patients who underwent surgery for BPH and received standard postoperative treatment. To assess erectile dysfunction, the IIEF-5 questionnaire was used 3 and 6 months after surgery. All statistical analysis procedures were performed using the SPSS 20 program. For qualitative data, the significance of differences in groups was determined by calculating the Chi-square (χ2) test. For quantitative data, the result was expressed as the median and 25-75 percentiles. Calculations of the significance of differences were made using the Mann-Whitney test.
Results. A statistically significant improvement in the erectile function of patients in both the main and control groups was established after surgery for 6 months (χ2 = 115.356; p < 0.001; χ2 = 115.034; p < 0.001, respectively). At the same time, in the main study group, the indicators had statistically significant differences with the control group. A twofold decrease in subjective symptoms of erectile dysfunction was shown in all patients, however, in the main study group, changes in these indicators were statistically significantly more pronounced (p=0.014 after 3 months; p=0.007 after six months).
Conclusion. The high efficiency of the prophylactic use of 5-fluorouracil by irrigation of the bladder and urethra in relation to the erectile function of patients who underwent surgery for benign prostatic hyperplasia was established.
Yerbol М. Kairambayev1, https://orcid.org/0000-0002-1399-1451
Tolkyn А. Bulegenov1, https://orcid.org/0000-0001-6392-2748
Kuat D. Akimzhanov1, Muratkan Т. Kuderbayev1, Alexander I. Neimark2,
Yerbol M. Smail1, https://orcid.org/0000-0003-3881-3747
Oxana A. Yurkovskaya1, https://orcid.org/0000-0002-4336-159X
Zhanar М. Zhumanbayeva1, https://orcid.org/0000-0001-8941-862X
Nataliya E. Glushkova3, https://orcid.org/0000-0003-1400-8436
1 NСJSC «Semey State Medical University», Semey, Republic of Kazakhstan;
2 Altay State Medical University, Barnaul, Russian Federation;
3 Al-Farabi Kazakh National University, Almaty, Republic of Kazakhstan.
1. Alexandrescu D., Fabi S., Yeh L.C., Fitzpatrick R.E., Goldman M.P. Comparative results in treatment of keloids with Intralesional 5- FU/Kenalog, 5-FU/Verapamil, Enalapril Alone, Verapamil Alone, and Laser: a case report and review of the literature // J Drug Dermatol. 2016. Vol. 15. Р.1442–1447.
2. Bapir R., Bhatti K.H., Eliwa A., García-Perdomo H.A., Gherabi N., Hennessey D., Magri V., Mourmouris P. et al. Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis // Arch Ital Urol Androl. 2022. Vol.94(2). Р.252-263.
3. Bijlard E., Steltenpool S., Niessen F.B. Intralesional 5- fluorouracil in keloid treatment: a systematic review // Acta Dermato-Venereol. 2015. Vol. 95. Р. 778–782.
4. European Association of Urology «Guidelines on Begin Prostatic Hyperplasia» Update March 2004 http://www. urotoday.com/images/stories/documents/prod/ (August, 2004).
5. Favorito L.A. Urethral stricture: the oldest urologic disease in 2017 // Int Braz J Urol. 2017. Vol.43(1). Р.1-2.
6. Hietanen K.E., Järvinen T.A., Huhtala H., Tolonen T.T., Kuokkanen H.O., Kaartinen I.S. Treatment of keloid scars with intralesional triamcinolone and 5-fluorouracil injections - a randomized controlled trial // J Plast Reconstr Aesthet Surg. 2019. Vol.72(1). Р. 4-11.
7. Jones M., Steggall M., Gelbart M. Catheterisation. Indwelling catheters in adults. City University, London 2012, 19 p.
8. Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting // Can J Urol. 2012. Vol.19 (Suppl 1). Р.10–17.
9. King C., Rourke K.F. Urethral Stricture is Frequently a Morbid Condition: Incidence and Factors Associated With Complications Related to Urethral Stricture // Urology. 2019. Vol.132. Р.189-194.
10. Langan R.C. Benign Prostatic Hyperplasia // Prim Care. 2019. Vol.46(2). Р.223-232.
11. Lokeshwar S.D., Harper B.T., Webb E., Jordan A., Dykes T.A., et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia // Transl Androl Urol. 2019. Vol.8(5). Р.529-539.
12. McVary K.T. BPH: epidemiology and comorbidities // Am J Manag Care. 2006. Vol.12 (5 suppl): P.122–128.
13. McVary K.T., Roehrborn C.G., Avins A.L. Update on AUA guideline on the management of benign prostatic hyperplasia // J Urol. 2011. Vol.185(5). Р.1793–1803.
14. Montiel-Jarquín A.J., Gutiérrez-Quiroz C.T., Pérez-Vazquez A.L., Ortiz-Agustín J.J., Garcia-Galicia A., Loría-Castellanos J. Quality of life and erectile dysfunction in patients with benign prostatic hyperplasia // Cir Cir. 2021. Vol.89(2). Р. 218-222.
15. Oka A.A.G., Duarsa G.W.K., Novianti P.A., Mahadewa T.G.B., Ryalino C. The impact of prostate-transurethral resection on erectile dysfunction in benign prostatic hyperplasia // Res Rep Urol. 2019. Vol.11. Р.91-96.
16. Parsons J.K., Im R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia // J Urol. 2009. Vol.182. Р.1463–1468.
17. Sangkum P., Levy J., Yafi F.A., Hellstrom W.J. Erectile dysfunction in urethral stricture and pelvic fracture urethral injury patients: diagnosis, treatment, and outcomes // Andrology. 2015. Vol.3(3). Р.443-449.
18. Sarma A.V., St Sauver J.L., Hollingsworth J.M. Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men // Urology. 2012. Vol.79. Р.102–108.
19. van Kollenburg R.A.A., de Bruin D.M., Wijkstra H. Validation of the Electronic Version of the International Index of Erectile Function (IIEF-5 and IIEF-15): A Crossover Study // J Med Internet Res. 2019. Vol.21(7). e13490.
20. Zhou W., Yu Q., Ma J., Xu C., Wu D., Li C. Triamcinolone acetonide combined with 5-fluorouracil suppresses urethral scar fibroblasts autophagy and fibrosis by increasing miR-192-5p expression // Am J Transl Res. 2021. Vol.13(6). Р.5956-5968.
Number of Views: 95
Category of articles:
Original articles
Bibliography link
Kairambayev Ye.М., Bulegenov T.А., Akimzhanov K.D., Kuderbayev M.Т., Neimark A.I., Smail. Ye.M., Yurkovskaya O.A., Zhumanbayeva Zh.М., Glushkova N.E. Evaluation of the efficacy 5-fluorouracil on erectile function in patients under surgical treatment of benign prostate hyperplasia // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 2, pp. 105-110. doi 10.34689/SH.2023.25.2.015Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS